P1/2, N=28, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P2, N=30, Enrolling by invitation, Chinese University of Hong Kong

To further boost the tumoricidal effects of RT-MPs, we developed innovative chemoradiotherapy-integrated tumor cell-derived microparticles (CR-MPs) by loading RT-MPs with chemotherapeutic agents, including methotrexate (MTX), monomethyl auristatin E (MMAE), or doxorubicin (DOX). In murine MPE models, CR-MPs effectively suppressed tumor progression, extended survival, and demonstrated favorable biosafety. When combined with immunotherapy, this approach achieved a cure rate of up to 70%, induced durable immunological memory, and retained efficacy against chemotherapy-resistant tumors. This study establishes CR-MPs as a novel platform with robust therapeutic efficacy against MPE, highlighting their translational potential as a precision concurrent chemoradiotherapy strategy for MPE management in clinical settings.

This study suggests that targeting cardiomyocyte ferroptosis mediated by the ALOX5 metabolism axis may represent a therapeutic strategy for DIC.

The most potent derivative 6H had an IC₅₀ value of 1.43 ± 0.18 μM, while compound 6D had an IC₅₀ value of 1.56 ± 0.30 μM compared to the standard drug doxorubicin...The results from the molecular docking studies revealed that compound 6H had a favorable binding mode within the PIM-1 kinase active site by hydrogen bonding and hydrophobic interactions with some amino acid residues within the enzyme's active site. The results from this investigation revealed that benzylidene-substituted pyrazolo[3,4-b]pyridine derivatives are potential anticancer agents that could be developed as potential anticancer drug candidates by inhibiting PIM-1 kinase activity.

P1, N=84, Recruiting, HighField Biopharmaceuticals Corporation | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Apr 2025 --> Jun 2027

Additionally, the OHCC potentiated the antiproliferative effect of doxorubicin, as evidenced by a raised Bax/Bcl-2 ratio and caspase 9 content, and suppressed VEGF levels...The histopathological investigation supported the apoptotic and necrotic death of cancer cells. These findings suggest that HCCs represent a promising nanocarrier system for the targeted parenteral delivery of FEL in cancer therapy.

Compound 2c exhibited potent activity against the colon cancer cell line HCT116 with an IC₅₀ of 5.17 ± 0.48 μM and a selectivity index (SI) of ≈3.42, outperforming the positive control doxorubicin (DOX, SI ≈ 2.19)...In a mouse colon cancer graft model, compound 2c achieved a 49.70% tumor inhibition rate at a dose of 20 mg/kg, with no obvious abnormalities observed in major organs. In conclusion, 2c is an effective mitochondrial MTHFD2 inhibitor with potential to develop into a potent anti-colon cancer drug.

Centering this chemo-photodynamic-immunotherapeutic cascade on enhanced ROS, ID-TEX concurrently improves efficacy, reduces toxicity, and strengthens immune modulation, underscoring strong translational potential for precision OSCC therapy.

Furthermore, CDDO-Me did not compromise the antitumor efficacy of DOX/LAP in breast cancer cells. CDDO-Me protects against DOX/LAP-induced cardiotoxicity by stabilizing GPX4 and inhibiting ferroptosis, offering a promising therapeutic strategy that preserves cardiac function without interfering with chemotherapy.

These updated European guidelines provide a comprehensive framework for standardized, high-quality care in stage I-III SCLC and establish a reference standard to harmonize radiotherapy approaches and inform the design of upcoming clinical trials.

By introducing small molecules such as pixantrone dimaleate (PIX) as molecular fillers, the stability of the DNA nanomaterials and the detection sensitivity of the detection system were significantly improved...Analysis of 60 clinical samples demonstrated that the system could effectively distinguish non-metastatic and metastatic patients, achieving high specificity (91.9%) and sensitivity (95.7%), and the results were consistent with clinical diagnosis. This study provided an effective liquid biopsy strategy for monitoring lung cancer metastasis risk.